CD19 and plasma cell myeloma: However, only targeting CD19 did not show considerable efficacy in most refractory multiple myeloma (MM) patients, partly due to the lower expression of CD19 on the cell surface of myeloma, and there is no FDA-approved CAR-T cell therapy against it (22, 32, 33).